SEC Form 4 · accession 0001190725-17-000026
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher C. Lemasters
Officer — EVP, Chief Business Officer
Period of report
Jan 26, 2017
Accepted (ET)
Jan 30, 2017 · 5:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option Grant (Right to Buy)F1 | $5.40 | Jan 26, 2017 | A | 11,250 | A | — | Jan 25, 2027 | Common Stock | 11,250 | 11,250 | D |
Explanation of responses
- F11/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.